First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility. // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000446?dgcid=rss_sd_all
First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility. JAAD International. https://www.sciencedirect.com/science/article/pii/S3117504X26000446?dgcid=rss_sd_all
“First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility.” JAAD International.
@article{article5821,
title = {First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000446?dgcid=rss_sd_all}
}